Debanjan Ray, Synthekine CEO
January 6, 2023 08:00 AM ESTUpdated January 9, 04:32 PM
Financing
Startups
Cell/Gene Tx

Syn­thekine nabs $100M to boost IL-2 pro­grams af­ter ri­vals hit set­backs

Kyle LaHucik

Senior Reporter

Syn­thekine reeled in a $100 mil­lion fi­nanc­ing to bankroll its IL-2 am­bi­tions and get in­to the clin­ic with its first CAR-T.

The Se­ries C fundraise …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

FDA ap­proves Io­n­is’ treat­ment for a rare meta­bol­ic dis­or­der

A service from the Financial Times